NCT05602818View on ClinicalTrials.gov

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

June 29, 2023

Study Completion Date

July 7, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Soticlestat 300 mg

Administered orally.

DRUG

Soticlestat 600 mg

Administered orally.

DRUG

Soticlestat 900 mg

Administered orally.

DRUG

Alprazolam

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

66212

Altasciences, Overland Park

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY